<DOC>
	<DOC>NCT00964873</DOC>
	<brief_summary>An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.</brief_summary>
	<brief_title>A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Subjects with a pathologic confirmation of the diagnosis of AML, ALL, or blastphase CML ECOG Performance Status 02 Adequate organ function as defined in the protocol. Ability to understand and willingness to sign a written informed consent document. Hyperleukocytosis Acute Promyelocytic Leukemia (FABM3) subtype Uncontrolled Disseminated Intravascular Coagulation (DIC) Active central nervous system leukemia Concomitant radiation therapy, chemotherapy, or immunotherapy Women who are pregnant or lactating Neuropathy â‰¥ grade 2 (NCI CTCAE) at time of enrollment Chemotherapy (with the exception of hydroxyurea) or radiotherapy within two weeks or within six times the agent's half life Require ongoing therapy with either G or GMCSF, or longacting versions of these molecules Use of any investigational agents within two weeks or within six times the agent's half life Treatment with chronic immunosuppressants Other medical/psychiatric condition that may increase the risk associated with study participation as defined by the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Synta</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
	<keyword>Hematologic Cancers</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Blast-phase Chronic Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>HSP90 Inhibitor</keyword>
</DOC>